RANI (Rani Therapeutics Holdings, Inc.) Short-Term Debt to Capital

Corporate company logo of Rani Therapeutics Holdings (RANI)

Rani Therapeutics (RANI) creates innovative RaniPill capsules to replace injections, raising funds through licenses with market leaders. A team of engineers and biologists is developing "smart pills," receiving options for breakthroughs. This chart on GURU.Markets for the separate_debt_short_eq metric shows 0.03. Future growth relies on the success of clinical trials and the management of R&D expenses.

Ratio of Short-Term Indebtedness to Capital: ranitherapeutics.com (RANI) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Rani Therapeutics

- stock quotes and analyst forecast:
Stock Price Rani Therapeutics|RANI - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Rani Therapeutics Holdings|RANI - Enterprise Value
- book capitalization information:
Net Assets per Single Share Rani Therapeutics|RANI - Accounting Value of Company|Market Value to Book Value Ratio ranitherapeutics.com|RANI - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Rani Therapeutics|RANI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Rani Therapeutics|RANI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Rani Therapeutics Holdings|RANI - Long-Term Debt|Company Current Liabilities Rani Therapeutics|Quick Ratio ranitherapeutics.com
- company profitability and valuation multiples indicators:
RANI - Final Profit
Fundamental valuation:RANI Rani Therapeutics Holdings, Inc.
Brand item of ranitherapeutics.com

For Rani Therapeutics (RANI), which monetizes its innovative "robo-pill" through licensing agreements, the ratio of short-term liabilities to equity reflects the balance between operational development and debt load. This coefficient measures the proportion of liabilities with a maturity exceeding one year within the capital structure, where increasing values indicate heightened financial risks, while a decrease confirms the issuer's solvency stability.

Competitors of Rani Therapeutics (RANI)

Short-Term Debt to Capital HLN|KVUE (Kenvue Health) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VRNA (Verona Pharma plc)|Short-Term Debt to Capital jyongbio.com MENS|LGND - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AMRX (Amneal Pharmaceuticals, Inc.)|Perrigo Company (PRGO) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Alvotech Biopharmaceuticals|LQDA (Liquidia Corporation) - Short-Term Debt to Capital|Short-Term Debt to Capital glpg.com|Short-Term Debt to Equity Ratio ANIP (ANI Pharmaceuticals, Inc.)|MNKD (MannKind Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amphastar AMPH|Pacira Corp (PCRX) - Current Liabilities to Capital|SPRY: Short-Term Debt to Equity Ratio|theravance.com - Short-Term Loans to Capital Ratio|AQST: Short-Term Debt to Capital|scPharmaceuticals - Ratio of Short-Term Indebtedness to Capital|TECX (Tectonic Therapeutic Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Tonix Pharmaceuticals Holding TNXP|Short-Term Debt to Equity China SXT Pharmaceuticals (SXTC)|EPRX (eupraxiapharma.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity BioHarvest Sciences Inc. BHST|Ratio of Short-Term Indebtedness to Capital EXOZ|Oramed Pharma - Short-Term Debt to Capital|ENTX - Short-Term Debt to Capital|MindWalk Holdings (HYFT) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio ABVC|CPIX (Cumberland Pharmaceuticals Inc.) - Short-Term Debt to Capital|Quantum BioPharma Ltd. (QNTM) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio FGEN (FibroGen Corp)|TELO (Telomir Pharmaceuticals Corp) - Ratio of Short-Term Indebtedness to Capital|Synergy CHC - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio RLYB (Rallybio Corp)|Lexaria - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital PULM (Pulmatrix Inc)|PTHL: Short-Term Debt to Capital|Current Liabilities to Capital Aptorum Group (APM)|Short-Term Debt to Equity Lyra Therapeutics, Inc.|IBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital TNFA|Short-Term Debt to Capital cbdmd.com (YCBD)|Short-Term Debt to Equity PainReform Limited PRFX|CYTO (Altamira Therapeutics Ltd) - Current Liabilities to Equity|Lipella Pharmaceuticals - Short-Term Debt to Capital|Current Liabilities to Capital optinose.com|PIRS (Pieris Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|Procaps Group (PROC) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio PTPI|QLI (Qilian International Corp) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital SLRN|Short-Term Debt to Capital Coefficient tffpharma.com